全文获取类型
收费全文 | 146590篇 |
免费 | 10268篇 |
国内免费 | 4216篇 |
专业分类
耳鼻咽喉 | 2027篇 |
儿科学 | 2876篇 |
妇产科学 | 2130篇 |
基础医学 | 7669篇 |
口腔科学 | 3330篇 |
临床医学 | 16416篇 |
内科学 | 20382篇 |
皮肤病学 | 2432篇 |
神经病学 | 7220篇 |
特种医学 | 4426篇 |
外国民族医学 | 39篇 |
外科学 | 22103篇 |
综合类 | 20655篇 |
现状与发展 | 23篇 |
一般理论 | 2篇 |
预防医学 | 6077篇 |
眼科学 | 2226篇 |
药学 | 11243篇 |
86篇 | |
中国医学 | 11143篇 |
肿瘤学 | 18569篇 |
出版年
2024年 | 342篇 |
2023年 | 2596篇 |
2022年 | 4757篇 |
2021年 | 6310篇 |
2020年 | 5853篇 |
2019年 | 5395篇 |
2018年 | 5143篇 |
2017年 | 5433篇 |
2016年 | 5785篇 |
2015年 | 5654篇 |
2014年 | 10303篇 |
2013年 | 12541篇 |
2012年 | 8653篇 |
2011年 | 9260篇 |
2010年 | 7817篇 |
2009年 | 7276篇 |
2008年 | 7021篇 |
2007年 | 7443篇 |
2006年 | 6593篇 |
2005年 | 5845篇 |
2004年 | 4758篇 |
2003年 | 4195篇 |
2002年 | 3483篇 |
2001年 | 3050篇 |
2000年 | 2476篇 |
1999年 | 1946篇 |
1998年 | 1600篇 |
1997年 | 1339篇 |
1996年 | 1153篇 |
1995年 | 994篇 |
1994年 | 793篇 |
1993年 | 608篇 |
1992年 | 527篇 |
1991年 | 497篇 |
1990年 | 423篇 |
1989年 | 360篇 |
1988年 | 349篇 |
1987年 | 301篇 |
1986年 | 256篇 |
1985年 | 309篇 |
1984年 | 285篇 |
1983年 | 205篇 |
1982年 | 208篇 |
1981年 | 193篇 |
1980年 | 165篇 |
1979年 | 164篇 |
1978年 | 111篇 |
1977年 | 56篇 |
1976年 | 75篇 |
1975年 | 65篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
11.
Alessandro Vatrella Angelantonio Maglio Corrado Pelaia Girolamo Pelaia Carolina Vitale 《Expert opinion on pharmacotherapy》2020,21(12):1505-1515
ABSTRACT
Introduction
‘Critical Asthma Syndrome’ (CAS) is an umbrella term proposed to include several forms of asthma, responsible for acute and life-threatening exacerbations. CAS requires urgent and adequate supportive and pharmacological treatments to prevent serious outcomes. 相似文献12.
An-feng TAO Zheng-hao XU Cheng-hao WU Yi WANG Wei-wei HOU Shi-hong ZHANG Zhong CHEN 《浙江大学学报(医学版)》2015,44(3):315
目的观察比较不同脉冲波形的低频率电刺激对海马电点燃癫痫模型小鼠的作用差异。方法采用电点燃刺激法建立小鼠癫痫模型, 观察正弦波、单相方波、双相方波低频率电刺激对模型小鼠癫痫行为发作及后放电持续时间的影响, 并比较不同时间点给予正弦波低频率电刺激的抗癫痫作用。结果与对照组比较, 正弦波低频率电刺激30 s能降低小鼠海马电点燃癫痫发作等级(2.85 ± 0.27 vs 4.75 ±0.12, P < 0.05)、减少大发作概率(53.6% vs 96.5%, P < 0.01) 和缩短后放电持续时间[(16.22 ± 1.69) s vs (30.29 ± 1.12) s, P < 0.01], 而单相方波和双相方波低频率电刺激30 s没有明显的抗癫痫作用。常用的单相方波低频率电刺激15 min能降低小鼠海马电点燃发作等级(3.58 ± 0.16, P < 0.05)、减少大发作概率(66.7%, P < 0.01);但对海马后放电持续时间及大发作持续时间无影响(均 P>0.05)。此外, 电点燃刺激前预先给予或结束后3 s内给予正弦波低频率电刺激具有明显的抗癫痫作用( P < 0.05或 P < 0.01), 而电点燃刺激结束10 s给予正弦波低频率电刺激则无上述抗癫痫作用。 结论低频率电刺激抗癫痫作用受波形参数的影响, 其中正弦波低频率电刺激能有效抑制小鼠海马电点燃癫痫的发作。 相似文献
13.
Rosario Gulias-Cañizo Anell Lagunes-Guillén Arturo González-Robles Erika Sánchez-Guzmán Federico Castro-Muñozledo 《Burns : journal of the International Society for Burn Injuries》2019,45(2):398-412
Background
Since recent reports have shown that (-)-Epigallocatechin-3-gallate (EGCG) could be used for treating proliferative and inflammatory disorders, we explored its use for the management of corneal chemical burns.Materials and methods
Initially, EGCG was assayed on the rabbit corneal epithelial cell line RCE1(5T5) to establish the best testing conditions, and to avoid unwanted outcomes in the experimental animals. Then, we studied its effects on cell proliferation, cell cycle progression and cell differentiation. Afterwards, we instilled EGCG in experimental grade II corneal alkali burns in mice, three times a day up to 21 days, and evaluated by slit lamp examination and histological sections of corneal epithelial, corneal endothelial and stromal edema, as well as the presence of inflammatory cells and neovascularization.Results
EGCG reduced cell growth and led to a decline in the proportion of proliferative cells in a concentration dependent manner. At 10 μM, EGCG promoted cell differentiation, an effect not related with apoptosis or cytotoxicity. When 10 μM EGCG was instilled in corneal alkali burns in mice three times a day up to 21 days, EGCG significantly reduced corneal opacity and neovascularization. The improved clinical appearance of the cornea was associated to a controlled epithelial growth; epithelial morphology was similar to that observed in normal epithelium and contrasted with the hyperproliferative, desquamating epithelium observed in control burn wounds. EGCG reduced corneal, stromal and endothelial edema, and wound inflammation.Conclusion
This work constitutes the first evidence for the use of EGCG in the acute phase of a corneal alkali burn, representing a possible novel alternative to improve patient outcomes as an add-on therapy. 相似文献14.
15.
16.
《Urologic oncology》2015,33(5):217-225
Although both surgery and radiation are potential curative options for men with clinically localized prostate cancer, a significant proportion of men with high-risk and locally advanced disease will demonstrate biochemical and potentially clinical progression of their disease. Neoadjuvant systemic therapy before radical prostatectomy (RP) is a logical strategy to improve treatment outcomes for men with clinically localized high-risk prostate cancer. Furthermore, delivery of chemotherapy and other systemic agents before RP affords an opportunity to explore the efficacy of these agents with pathologic end points.Neoadjuvant chemotherapy, primarily with docetaxel (with or without androgen deprivation therapy), has demonstrated feasibility and safety in men undergoing RP, but no study to date has established the efficacy of neoadjuvant chemotherapy or neoadjuvant chemohormonal therapies. Other novel agents, such as those targeting the vascular endothelial growth factor receptor, epidermal growth factor receptor, platelet-derived growth factor receptor, clusterin, and immunomodulatory therapeutics, are currently under investigation. 相似文献
17.
18.
19.
20.
《The Journal of thoracic and cardiovascular surgery》2023,165(1):149-158.e4
BackgroundCoronary artery bypass grafting (CABG) improves survival in patients with heart failure and severely reduced left ventricular systolic function (LVEF). Limited data exist regarding adverse cardiovascular event rates after CABG in patients with heart failure with midrange ejection fraction (HFmrEF; LVEF > 40% and < 55%).MethodsWe analyzed data on isolated CABG patients from the Veterans Affairs national database (2010-2019). We stratified patients into control (normal LVEF and no heart failure), HFmrEF, and heart failure with reduced LVEF (HFrEF) groups. We compared all-cause mortality and heart failure hospitalization rates between groups with a Cox model and recurrent events analysis, respectively.ResultsIn 6533 veterans, HFmrEF and HFrEF was present in 1715 (26.3%) and 566 (8.6%) respectively; the control group had 4252 (65.1%) patients. HFrEF patients were more likely to have diabetes mellitus (59%), insulin therapy (36%), and previous myocardial infarction (31%). Anemia was more prevalent in patients with HFrEF (49%) as was a lower serum albumin (mean, 3.6 mg/dL). Compared with the control group, a higher risk of death was observed in the HFmrEF (hazard ratio [HR], 1.3 [1.2-1.5)] and HFrEF (HR, 1.5 [1.2-1.7]) groups. HFmrEF patients had the higher risk of myocardial infarction (subdistribution HR, 1.2 [1-1.6]; P = .04). Risk of heart failure hospitalization was higher in patients with HFmrEF (HR, 4.1 [3.5-4.7]) and patients with HFrEF (HR, 7.2 [6.2-8.5]).ConclusionsHeart failure with midrange ejection fraction negatively affects survival after CABG. These patients also experience higher rates myocardial infarction and heart failure hospitalization. 相似文献